RT Journal Article
SR Electronic
T1 Cetuximab associated dermal filler reaction
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e228882
DO 10.1136/bcr-2018-228882
VO 12
IS 8
A1 Shivanshan Pathmanathan
A1 Marcin Dzienis
YR 2019
UL http://casereports.bmj.com/content/12/8/e228882.abstract
AB A 52-year-old male patient with hyaluronic acid-based dermal fillers injected in his cheeks was diagnosed with glossotonsillary malignancy, and managed with concurrent cetuximab (epidermal growth factor receptor inhibitor) and radiation therapy. He developed significant inflammation around the dermal filler sites after first cycle of cetuximab which improved with dissolution of the dermal fillers with hyaluronidase. This suggests that cetuximab can lead to inflammation around the dermal filler sites, which can be treated with dissolution of the filler.